Immunthrombozytopenie - aktuelle Diagnostik und Therapie: Empfehlungen einer gemeinsamen Arbeitsgruppe der DGHO, ÖGHO, SGH, GPOH und DGTI

Matzdorff, Axel; Meyer, Oliver; Ostermann, Helmut; Kiefel, V.; Eberl, W.; Kühne, Thomas; Pabinger, Ingrid; Rummel, Matthias

doi:10.1159/000486384

Cited by 11 publications

(8 citation statements)

References 135 publications

(68 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Immune thrombocytopenia (ITP) is an autoimmune disorder, characterized by transient or persistent decrease of the platelet count (less than 100 × 10 9 /l) [1][2][3]. The incidence is estimated to be 1.9-6.4/100,000 children per year and 3.3/100,000 adults per year [4].…”

Section: Introductionmentioning

confidence: 99%

Disease management of patients with immune thrombocytopenia—results of a representative retrospective survey in Germany

Kubasch

Kisro²,

Heßling

et al. 2020

Ann Hematol

View full text Add to dashboard Cite

Clinical research has resulted in an improvement of treatment options for patients with immune thrombocytopenia (ITP) over the last years. However, only few data exist on the real-life management of patients with ITP. To expand the knowledge, a multicenter, national survey was undertaken in 26 hematology practices distributed all over Germany. All patients with a diagnosis of ITP were documented using questionnaires, irrespective of the diagnosis date over a period of 2 years. Overall, data of 1023 patients were evaluated with 56% of patients being older than 60 years. Seventy-nine percent of the patients had chronic (> 12 months), 16% persistent (> 3–12 months), and 5% newly diagnosed (0–3 months) ITP. In 61% of cases, the disease lasted 3 or more years before survey documentation started. Main strategies applied as first-line therapy consisted of steroids in 45% and a “watch and wait” approach in 41% of patients. During second- and third-line strategies, treatment with steroids decreased (36% and 28%, respectively), while treatment modalities such as TPO-RAs increased (19% and 26%, respectively). As expected, patients with a low platelet count and thus a higher risk for bleeding and mortality received treatment (esp. steroids) more frequently during first line than those with a higher platelet count. Up to a third of patients were treated with steroids for more than a year. Overall, our study provides a cross-section overview about the current therapeutic treatment landscape in German ITP patients. The results will help to improve therapeutic management of ITP patients.

show abstract

Section: Introductionmentioning

confidence: 99%

Disease management of patients with immune thrombocytopenia—results of a representative retrospective survey in Germany

Kubasch

Kisro²,

Heßling

et al. 2020

Ann Hematol

View full text Add to dashboard Cite

show abstract

“…21 The disease has also a major impact on the healthcare (treatment costs) and socio-economic (family, employment) system. 22 DIAGNOSTIC WORK UP 1,3,23,24 BASIC EVALUATION • Treatment is mandatory in patients with "active bleeding" OR "platelets <10 x 10 9 /L". • Treatment is generally recommended in patients with "No or mild bleeding" AND "platelets 10-30 x 10 9 /L".…”

Section: Consequences Of Itp Diagnosismentioning

confidence: 99%

“…27 In daily clinical practice, the decision to hospitalise a patient with ITP is based not only on platelet count but on the presence of bleeding symptoms and on factors influencing the bleeding risk as age, comorbidities, need of treatment with anticoagulant or antiplatelet agents, uncertainty of diagnosis, newly diagnosed vs. chronic disease, refractoriness of the disease, easy access to care facilities, social concerns, etc. 23,24,27 Newly diagnosed ITP patients are managed with corticosteroids with or without intravenous immunoglobulins (IgIV) depending on the severity of thrombocytopenia and/or of the bleeding signs and symptoms. Although impressive responses are seen using these agents, the responses are usually short lived.…”

Section: When Is Hospitalisation Of Itp Justified?mentioning

confidence: 99%

Primary immune thrombocytopenia in adults: Belgian recommendations for diagnosis and treatment anno 2021 made by the Belgian Hematology Society

Janssens

Selleslag

Depaus

et al. 2021

Acta Clinica Belgica

View full text Add to dashboard Cite

“…Eine neue Einteilung in 3 Krankheits-und Therapiephasen wurde entwickelt und von den Leitlinien übernommen (▶ Tab. 3) [2,4,5].…”

Section: Stadieneinteilung Und Therapiezieleunclassified

Diagnostik und Therapie der Immunthrombozytopenie

Matzdorff

Wörmann

2018

Dtsch med Wochenschr

Self Cite

View full text Add to dashboard Cite

Immune thrombocytopenia (ITP) is a heterogeneous disease. Diagnosis of primary ITP continues to be based on the exclusion of all known causes for secondary ITP. The new ITP classification distinguishes three categories. First line treatment consists of either dexamethasone or prednisone. The most effective options in second line treatment are splenectomy or thrombopoietin receptor agonists. The medical societies for hematology and oncology of the German-speaking countries have recently updated their guidelines on ITP.

show abstract

Immunthrombozytopenie - aktuelle Diagnostik und Therapie: Empfehlungen einer gemeinsamen Arbeitsgruppe der DGHO, ÖGHO, SGH, GPOH und DGTI

Cited by 11 publications

References 135 publications

Disease management of patients with immune thrombocytopenia—results of a representative retrospective survey in Germany

Disease management of patients with immune thrombocytopenia—results of a representative retrospective survey in Germany

Primary immune thrombocytopenia in adults: Belgian recommendations for diagnosis and treatment anno 2021 made by the Belgian Hematology Society

Diagnostik und Therapie der Immunthrombozytopenie

Contact Info

Product

Resources

About